Project Description:

Although ovarian cancer can be initially responsive to platinum-based chemotherapy, approximately 90% of patients later find that the disease becomes resistant to this disease, and treatment options haven’t significantly expanded in three decades. This leaves many patients without promising treatment options. Dr Stephens’ team identified Keratin-14 (KRT14) as a viable target for a novel immunotherapy that could assist with preventing metastasis. In this project the team aimed to identify the best way to target KRT14, to investigate any molecular changes that occurred between tumour cells and KRT14 and generate a proof-of-principle study.